Neoadjuvant/presurgical treatments

Breast Cancer Research

Table 1 End-points in current neoadjuvant chemotherapy trials

Trial	n	Primary end-point	Secondary end-point
GEPARDUO	913	Clinical OR	PathCR
NeoTANGO	800	PathCR	Clinical OR
NSABPB-40	1,200	PathCR	Clinical OR
GEPAR4	1,500	PathCR	Clinical OR
NOAH	288	PathCR	Clinical OR
PREPARE	733	DFS	PathCR
AGO	679	PathCR	Clinical OR
neoALTTO	450	PathCR	Clinical OR

Presented are some current neoadjuvant chemotherapy trials using clinical response and pathCR as primary or secondary end-points. DFS, disease-free survival; OR, overall response; pathCR, pathological complete remission.

ISSN: 1465-542X